Progression-Free Survival
Extended Data Fig 1. · Panel A
Panel A 是同一 Extended Data Fig 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope, Fernanda B Musa, Robert S Mannel, Mark S Shahin, Guilherme H Cantuaria, Eugenia Girda, Elizabeth Lokich, Juraj Kavecansky, Charles A Leath, Lilian T Gien, Emily M Hinchcliff, Shashikant B Lele, Lisa M Landrum, Floor Backes, Roisin E O'Cearbhaill, Tareq Al Baghdadi, Emily K Hill, Premal H Thaker, Veena S John, Stephen Welch, Amanda N Fader, Matthew A Powell, Carol Aghajanian
Nat Med 31(5) 1539-1546
Historically, the treatment of patients with advanced stage or recurrent endometrial cancer included paclitaxel plus carboplatin. Immunotherapy in combination with chemotherapy resulted in improved clinical outcomes in several solid tumors. In the phase 3 NRG GY018 study, pembrolizumab plus chemotherapy significantly improved investigator-assessed progression-free survival (PFS; primary endpoint) versus placebo plus chemotherapy in patients with advanced/metastatic/recurrent endometrial cancer regardless of mismatch repair status. Here we report on key secondary endpoints and exploratory analyses. Patients were women ≥18 years old with newly diagnosed stage III or IVA endometrial cancer with measurable disease, or stage IVB or recurrent endometrial cancer with or without measurable disease. Patients (n = 810) were randomized (1:1) to pembrolizumab or placebo plus paclitaxel-carboplatin followed by maintenance pembrolizumab or placebo for up to 24 months. Overall survival was a secondary endpoint and PFS per RECIST v.1.1 by blinded independent central review was an exploratory endpoint. Overall survival data were immature; hazard ratios favored pembrolizumab (mismatch repair-proficient: 0.79 (0.53-1.17); 1-sided nominal P = 0.1157; mismatch repair-deficient: 0.55 (0.25-1.19); 1-sided nominal P = 0.0617). Hazard ratios (95% confidence intervals) for PFS per blinded independent central review favored pembrolizumab (mismatch repair-proficient: 0.64 (0.49-0.85); P = 0.0008; mismatch repair-deficient: 0.45 (0.27-0.73); P = 0.0005). These findings further support the use of pembrolizumab plus chemotherapy as first-line treatment for patients with advanced stage or recurrent endometrial cancer regardless of mismatch repair status. ClinicalTrials.gov identifier: NCT03914612 .
2 个 Figure · 4 个 KM 面板
Kaplan-Meier–estimated PFS per RECIST v1.1 as assessed by the investigators in the dMMR population (A) with methylation and (B) with no methylation at interim analysis. Data cutoff date: December 16, 2022. a Based on a Cox regression model with the Efron method of tie handling with treatment as a covariate. CT, chemotherapy; dMMR, mismatch repair-deficient; HR, hazard ratio; NR, not reached; pembro, pembrolizumab; PFS, progression-free survival; pMMR, mismatch repair-proficient; RECIST, Response Evaluation Criteria in Solid Tumors.
Extended Data Fig 1. · Panel A
Panel A 是同一 Extended Data Fig 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig 1. · Panel B
Panel B 是同一 Extended Data Fig 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kaplan-Meier–estimated OS in the (A) pMMR and (B) dMMR populations at interim analysis. OS data were immature (27.2% information fraction for pMMR population [99/364 events needed for final analysis had occurred] and 18.0% information fraction for dMMR population [27/150 events needed for final analysis had occurred]). Tick marks indicated censored data. Data cutoff dates: December 6, 2022 (pMMR); December 16, 2022 (dMMR). a Follow-up duration is the time from randomization to the date of death or the database cutoff date if the participant is still alive. b Based on a Cox regression model with the Efron method of tie handling with treatment as a covariate stratified by prior chemotherapy. c One-sided P value based on log-rank test stratified by prior chemotherapy. CT, chemotherapy; dMMR, mismatch repair-deficient; HR, hazard ratio; OS, overall survival; NR, not reached; pembro, pembrolizumab; pMMR, mismatch repair-proficient.
这些图片未产生 KM 曲线结果,不在主页面重复展示。